Triggering of suicidal erythrocyte death by uremic toxin indoxyl sulfate

BMC Nephrology

Volumn 14, Issue 1, 2013, Pages

  Ahmed, Mohamed Siyabeldin E ^a   Abed, Majed ^a   Voelkl, Jakob ^a   Lang, Florian ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Calcium; Cell volume; Eryptosis; Indoxyl sulfate; Phosphatidylserine

Indexed keywords

CERAMIDE; HEMOGLOBIN; INDICAN; LIPOCORTIN 5; PHOSPHATIDYLSERINE;

ARTICLE; CELL DEATH; CELL MEMBRANE; CELL VOLUME; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; ERYPTOSIS; ERYTHROCYTE; EXTRACELLULAR CALCIUM; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HEMOGLOBIN DETERMINATION; HEMOLYSIS; HUMAN; HUMAN CELL;

APOPTOSIS; CALCIUM; CELL SIZE; CELLS, CULTURED; ERYTHROCYTE MEMBRANE; ERYTHROCYTES; GENES, TRANSGENIC, SUICIDE; HEMOLYSIS; HEMOLYTIC AGENTS; HUMANS; INDICAN; TOXINS, BIOLOGICAL;

EID: 84886744408     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-14-244     Document Type: Article

References (57)

1. Complications of progression of CKD. Yang M, Fox CH, Vassalotti J, Choi M, Adv Chronic Kidney Dis 2011 18 6 400 405 10.1053/j.ackd.2011.10.001 22098657
2. Association of anaemia in primary care patients with chronic kidney disease: cross sectional study of quality improvement in chronic kidney disease (QICKD) trial data. Dmitrieva O, de Lusignan S, Macdougall IC, Gallagher H, Tomson C, Harris K, Desombre T, Goldsmith D, BMC nephrology 2013 14 24 10.1186/1471-2369-14-24 23351270
3. Anemia in children with chronic kidney disease. Atkinson MA, Furth SL, Nat Rev Nephrol 2011 7 11 635 641 10.1038/nrneph.2011.115 21894183
4. Critical appraisal of randomized controlled trials of anemia correction in patients with renal failure. Parfrey PS, Curr Opin Nephrol Hypertens 2011 20 2 177 181 10.1097/MNH.0b013e3283428bc2 21157336
5. Managing erythropoietin hyporesponsiveness. Kwack C, Balakrishnan VS, Semin Dial 2006 19 2 146 151 10.1111/j.1525-139X.2006.00141.x 16551293 (Pubitemid 43468648)
6. Iron and clinical outcomes in dialysis and non-dialysis-dependent chronic kidney disease patients. Kovesdy CP, Adv Chronic Kidney Dis 2009 16 2 109 116 10.1053/j.ackd.2008.12.006 19233070
7. Red blood cell survival in long-term dialysis patients. Vos FE, Schollum JB, Coulter CV, Doyle TC, Duffull SB, Walker RJ, Am J Kidney Dis 2011 58 4 591 598 10.1053/j.ajkd.2011.03.031 21715072
8. Regulation of phosphatidylserine exposure in red blood cells. Nguyen DB, Wagner-Britz L, Maia S, Steffen P, Wagner C, Kaestner L, Bernhardt I, Cell Physiol Biochem 2011 28 5 847 856 10.1159/000335798 22178937
9. Killing me softly-suicidal erythrocyte death. Lang E, Qadri SM, Lang F, Int J Biochem Cell Biol 2012 44 8 1236 1243 10.1016/j.biocel.2012.04.019 22561748
10. Inhibition of erythrocyte cation channels by erythropoietin. Myssina S, Huber SM, Birka C, Lang PA, Lang KS, Friedrich B, Risler T, Wieder T, Lang F, J Am Soc Nephrol 2003 14 11 2750 2757 10.1097/01.ASN.0000093253.42641.C1 14569084 (Pubitemid 37305637)
11. In vitro effect of CTAB- and PEG-coated gold nanorods on the induction of eryptosis/erythroptosis in human erythrocytes. Lau IP, Chen H, Wang J, Ong HC, Leung KC, Ho HP, Kong SK, Nanotoxicology 2012 6 847 56 doi:10.3109/17435390. 2011.625132. Epub 2011 Oct 24 10.3109/17435390.2011.625132 22022996
12. Erythrocyte caspase-3 activation and oxidative imbalance in erythrocytes and in plasma of type 2 diabetic patients. Maellaro E, Leoncini S, Moretti D, Del Bello B, Tanganelli I, De Felice C, Ciccoli L, Acta Diabetol 2013 50 4 489 95 doi:10.1007/s00592-011-0274-0. Epub 2011 Mar 25 10.1007/s00592-011-0274-0 21437568
13. Janus kinase 3 is expressed in erythrocytes, phosphorylated upon energy depletion and involved in the regulation of suicidal erythrocyte death. Bhavsar SK, Gu S, Bobbala D, Lang F, Cell Physiol Biochem 2011 27 5 547 556 10.1159/000329956 21691072
14. Protein kinase CK1alpha regulates erythrocyte survival. Zelenak C, Eberhard M, Jilani K, Qadri SM, Macek B, Lang F, Cell Physiol Biochem 2012 29 1-2 171 180 22415086
15. Decreased redox-sensitive erythrocyte cation channel activity in aquaporin 9-deficient mice. Kucherenko YV, Huber SM, Nielsen S, Lang F, J Membr Biol 2012 245 12 797 805 doi:10.1007/s00232-012-9482-y. Epub 2012 Jul 27 10.1007/s00232-012-9482-y 22836670
16. p38 MAPK activation and function following osmotic shock of erythrocytes. Gatidis S, Zelenak C, Fajol A, Lang E, Jilani K, Michael D, Qadri SM, Lang F, Cell Physiol Biochem 2011 28 6 1279 1286 10.1159/000335859 22179015
17. Enhanced erythrocyte membrane exposure of phosphatidylserine following sorafenib treatment: an in vivo and in vitro study. Lupescu A, Shaik N, Jilani K, Zelenak C, Lang E, Pasham V, Zbidah M, Plate A, Bitzer M, Foller M, et al. Cell Physiol Biochem 2012 30 4 876 888 10.1159/000341465 22907570
18. Sunitinib-sensitive suicidal erythrocyte death. Shaik N, Lupescu A, Lang F, Cell Physiol Biochem 2012 30 3 512 522 10.1159/000341434 22814298
19. Inhibition of Ca(2+) entry and suicidal erythrocyte death by naringin. Shaik N, Zbidah M, Lang F, Cell Physiol Biochem 2012 30 3 678 686 10.1159/000341448 22854627
20. Tanshinone IIA stimulates erythrocyte phosphatidylserine exposure. Zelenak C, Pasham V, Jilani K, Tripodi PM, Rosaclerio L, Pathare G, Lupescu A, Faggio C, Qadri SM, Lang F, Cell Physiol Biochem 2012 30 1 282 294 10.1159/000339064 22759974
21. Dicoumarol activates Ca2 + -permeable cation channels triggering erythrocyte cell membrane scrambling. Qadri SM, Kucherenko Y, Zelenak C, Jilani K, Lang E, Lang F, Cell Physiol Biochem 2011 28 5 857 864 10.1159/000335800 22178938
22. Sphingosine but not sphingosine-1-phosphate stimulates suicidal erythrocyte death. Qadri SM, Bauer J, Zelenak C, Mahmud H, Kucherenko Y, Lee SH, Ferlinz K, Lang F, Cell Physiol Biochem 2011 28 2 339 346 10.1159/000331750 21865742
23. Stimulation of suicidal erythrocyte death by benzethonium. Lang E, Jilani K, Zelenak C, Pasham V, Bobbala D, Qadri SM, Lang F, Cell Physiol Biochem 2011 28 2 347 354 10.1159/000331751 21865743
24. The NFkB pathway inhibitors Bay 11-7082 and parthenolide induce programmed cell death in anucleated erythrocytes. Ghashghaeinia M, Toulany M, Saki M, Bobbala D, Fehrenbacher B, Rupec R, Rodemann HP, Ghoreschi K, Rocken M, Schaller M, et al. Cell Physiol Biochem 2011 27 1 45 54 10.1159/000325204 21325821
25. Hemotrophic mycoplasmas induce programmed cell death in red blood cells. Felder KM, Hoelzle K, Ritzmann M, Kilchling T, Schiele D, Heinritzi K, Groebel K, Hoelzle LE, Cell Physiol Biochem 2011 27 5 557 564 10.1159/000329957 21691073
26. Enhanced apoptotic death of erythrocytes induced by the mycotoxin ochratoxin a. Jilani K, Lupescu A, Zbidah M, Abed M, Shaik N, Lang F, Kidney Blood Press Res 2012 36 1 107 118 10.1159/000341488 23095759
27. Ca influx versus efflux during eryptosis in uremic erythrocytes. Polak-Jonkisz D, Purzyc L, Blood Purif 2012 34 3-4 209 210 23095711
28. Sphingomyelinase-induced adhesion of eryptotic erythrocytes to endothelial cells. Abed M, Towhid ST, Mia S, Pakladok T, Alesutan I, Borst O, Gawaz M, Gulbins E, Lang F, Am J Physiol Cell Physiol 2012 303 9 991 999 10.1152/ajpcell.00239.2012 22954799
29. Differential erythropoietin action upon cells induced to eryptosis by different agents. Vota DM, Maltaneri RE, Wenker SD, Nesse AB, Vittori D, Cell Biochem Biophys 2013 65 2 145 57 doi:10.1007/s12013-012-9408-4 10.1007/s12013-012-9408-4 22903352
30. Increased caspase-3 immunoreactivity of erythrocytes in STZ diabetic rats. Firat U, Kaya S, Cim A, Buyukbayram H, Gokalp O, Dal MS, Tamer MN, Exp Diabetes Res 2012 2012 316384 22611373
31. Plasmodium falciparum-infected erythrocytes induce granzyme B by NK cells through expression of host-Hsp70. Bottger E, Multhoff G, Kun JF, Esen M, PLoS One 2012 7 3 33774 10.1371/journal.pone.0033774 22438997
32. The impact of erythrocyte age on eryptosis. Ghashghaeinia M, Cluitmans JC, Akel A, Dreischer P, Toulany M, Koberle M, Skabytska Y, Saki M, Biedermann T, Duszenko M, et al. Br J Haematol 2012 157 5 606 614 10.1111/j.1365-2141.2012. 09100.x 22429222
33. Polyphyllin D induces apoptosis in human erythrocytes through Ca(2)(+) rise and membrane permeabilization. Gao M, Cheung KL, Lau IP, Yu WS, Fung KP, Yu B, Loo JF, Kong SK, Arch Toxicol 2012 86 5 741 752 10.1007/s00204-012-0808-4 22349056
34. Understanding the mechanisms for metabolism-linked hemolytic toxicity of primaquine against glucose 6-phosphate dehydrogenase deficient human erythrocytes: evaluation of eryptotic pathway. Ganesan S, Chaurasiya ND, Sahu R, Walker LA, Tekwani BL, Toxicology 2012 294 1 54 60 10.1016/j.tox.2012.01.015 22330256
35. Deoxygenation-induced and Ca(2+) dependent phosphatidylserine externalisation in red blood cells from normal individuals and sickle cell patients. Weiss E, Cytlak UM, Rees DC, Osei A, Gibson JS, Cell Calcium 2012 51 1 51 56 10.1016/j.ceca.2011.10.005 22197026
36. Induction of programmed erythrocyte death by gambogic acid. Lupescu A, Jilani K, Zelenak C, Zbidah M, Shaik N, Lang F, Cell Physiol Biochem 2012 30 2 428 438 10.1159/000339036 22814240
37. Inhibitory effect of furosemide on Non-selective voltage-independent cation channels in human erythrocytes. Kucherenko YV, Lang F, Cell Physiol Biochem 2012 30 4 863 875 10.1159/000341464 22907543
38. The uremic toxin acrolein promotes suicidal erythrocyte death. Ahmed M, Langer H, Abed M, Voelkl J, Lang F, Kidney Blood Press Res 2013 37 158 167 10.1159/000350141 23712027
39. Normal and pathologic concentrations of uremic toxins. Duranton F, Cohen G, De Smet R, Rodriguez M, Jankowski J, Vanholder R, Argiles A, J Am Soc Nephrol 2012 23 7 1258 1270 10.1681/ASN.2011121175 22626821
40. Indoxyl sulfate, a uremic toxin, downregulates renal expression of Nrf2 through activation of NF-kappaB. Bolati D, Shimizu H, Yisireyili M, Nishijima F, Niwa T, BMC nephrology 2013 14 56 10.1186/1471-2369-14-56 23496811
41. Indoxyl sulfate, a representative uremic toxin, suppresses erythropoietin production in a HIF-dependent manner. Chiang CK, Tanaka T, Inagi R, Fujita T, Nangaku M, Lab Invest 2011 91 11 1564 1571 10.1038/labinvest.2011.114 21863063
42. Indoxyl sulfate induces nephrovascular senescence. Niwa T, Shimizu H, J Ren Nutr 2012 22 1 102 106 10.1053/j.jrn.2011.10.032 22200425
43. Benfotiamine exhibits direct antioxidative capacity and prevents induction of DNA damage in vitro. Schmid U, Stopper H, Heidland A, Schupp N, Diabetes Metab Res Rev 2008 24 5 371 377 10.1002/dmrr.860 18384109
44. The uremic solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair. Dou L, Bertrand E, Cerini C, Faure V, Sampol J, Vanholder R, Berland Y, Brunet P, Kidney Int 2004 65 2 442 451 10.1111/j.1523-1755.2004.00399.x 14717914 (Pubitemid 38130638)
45. Cardiorenal syndrome: pathophysiology, preclinical models, management and potential role of uraemic toxins. Liu S, Lekawanvijit S, Kompa AR, Wang BH, Kelly DJ, Krum H, Clin Exp Pharmacol Physiol 2012 39 8 692 700 10.1111/j.1440-1681.2011.05632.x 22014026
46. Uremic solutes from colon microbes. Meyer TW, Hostetter TH, Kidney Int 2012 81 10 949 954 10.1038/ki.2011.504 22318422
47. Indoxyl sulfate-induced epithelial-to-mesenchymal transition and apoptosis of renal tubular cells as novel mechanisms of progression of renal disease. Kim SH, Yu MA, Ryu ES, Jang YH, Kang DH, Lab Invest 2012 92 4 488 498 10.1038/labinvest.2011.194 22231736
48. Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Barreto FC, Barreto DV, Liabeuf S, Meert N, Glorieux G, Temmar M, Choukroun G, Vanholder R, Massy ZA, Clin J Am Soc Nephrol 2009 4 10 1551 1558 10.2215/CJN.03980609 19696217
49. Activation of calcium-dependent potassium channels in deoxygenated sickled red cells. Bookchin RM, Ortiz OE, Lew VL, Prog Clin Biol Res 1987 240 193 200 2441414
50. Eryptosis, a window to systemic disease. Lang F, Gulbins E, Lerche H, Huber SM, Kempe DS, Fller M, Cell Physiol Biochem 2008 22 5-6 373 380 19088418
51. Enhanced programmed cell death of iron-deficient erythrocytes. Kempe DS, Lang PA, Duranton C, Akel A, Lang KS, Huber SM, Wieder T, Lang F, FASEB J 2006 20 2 368 370 16371427 (Pubitemid 46671174)
52. Dynamic adhesion of eryptotic erythrocytes to endothelial cells via CXCL16/SR-PSOX. Borst O, Abed M, Alesutan I, Towhid ST, Qadri SM, Foller M, Gawaz M, Lang F, Am J Physiol Cell Physiol 2012 302 4 644 C651 10.1152/ajpcell.00340.2011 22173866
53. Lysophosphatidic acid induces thrombogenic activity through phosphatidylserine exposure and procoagulant microvesicle generation in human erythrocytes. Chung SM, Bae ON, Lim KM, Noh JY, Lee MY, Jung YS, Chung JH, Arterioscler Thromb Vasc Biol 2007 27 2 414 421 17110600
54. Surface exposure of phosphatidylserine in pathological cells. Zwaal RF, Comfurius P, Bevers EM, Cell Mol Life Sci 2005 62 9 971 988 10.1007/s00018-005- 4527-3 15761668 (Pubitemid 40655614)
55. What is causing the mortality in treating the anemia of chronic kidney disease: erythropoietin dose or hemoglobin level? Singh AK, Curr Opin Nephrol Hypertens 2010 19 5 420 424 10.1097/MNH.0b013e32833cf1d6 20689425
56. Hyporesponsiveness to erythropoietin: causes and management. Elliott J, Mishler D, Agarwal R, Adv Chronic Kidney Dis 2009 16 2 94 100 10.1053/j.ackd.2008.12.004 19233068
57. Intravenous iron versus erythropoiesis-stimulating agents: friends or foes in treating chronic kidney disease anemia? Kalantar-Zadeh K, Streja E, Miller JE, Nissenson AR, Adv Chronic Kidney Dis 2009 16 2 143 151 10.1053/j.ackd.2008.12.008 19233073